CA2080582A1 - Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase - Google Patents
Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinaseInfo
- Publication number
- CA2080582A1 CA2080582A1 CA002080582A CA2080582A CA2080582A1 CA 2080582 A1 CA2080582 A1 CA 2080582A1 CA 002080582 A CA002080582 A CA 002080582A CA 2080582 A CA2080582 A CA 2080582A CA 2080582 A1 CA2080582 A1 CA 2080582A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- patient
- cell proliferation
- patient suffering
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 74
- 102000001301 EGF receptor Human genes 0.000 title description 18
- 108060006698 EGF receptor Proteins 0.000 title description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 27
- 230000004663 cell proliferation Effects 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 25
- 125000003118 aryl group Chemical group 0.000 claims abstract description 15
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Chemical group 0.000 claims abstract description 11
- 125000002541 furyl group Chemical group 0.000 claims abstract description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 9
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 9
- 125000000165 tricyclic carbocycle group Chemical group 0.000 claims abstract description 4
- -1 aryl compound Chemical class 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- TTZDOBVWBQXGDC-UHFFFAOYSA-N 2-(3,4-dihydroxybenzoyl)-3-(1h-indol-3-yl)prop-2-enenitrile Chemical compound C1=C(O)C(O)=CC=C1C(=O)C(C#N)=CC1=CNC2=CC=CC=C12 TTZDOBVWBQXGDC-UHFFFAOYSA-N 0.000 claims 1
- TWEQSBKXFOZXRA-UHFFFAOYSA-N 2-(3,4-dihydroxybenzoyl)-3-(1h-indol-5-yl)prop-2-enenitrile Chemical compound C1=C(O)C(O)=CC=C1C(=O)C(C#N)=CC1=CC=C(NC=C2)C2=C1 TWEQSBKXFOZXRA-UHFFFAOYSA-N 0.000 claims 1
- AODLEOQMWSVSTN-UHFFFAOYSA-N 3-phenanthren-9-yl-2-pyridin-4-ylprop-2-enenitrile Chemical compound C=1C2=CC=CC=C2C2=CC=CC=C2C=1C=C(C#N)C1=CC=NC=C1 AODLEOQMWSVSTN-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 15
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 15
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 14
- 101800003838 Epidermal growth factor Proteins 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 229940116977 epidermal growth factor Drugs 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 13
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 13
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 13
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000035578 autophosphorylation Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical class N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000012458 free base Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000003746 Insulin Receptor Human genes 0.000 description 6
- 108010001127 Insulin Receptor Proteins 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 150000002431 hydrogen Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ADZUEEUKBYCSEY-UHFFFAOYSA-N 1h-indole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC=CC2=C1 ADZUEEUKBYCSEY-UHFFFAOYSA-N 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- KNNMPDDHEIGMJF-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-3-oxopropanenitrile Chemical compound OC1=CC=C(C(=O)CC#N)C=C1O KNNMPDDHEIGMJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000005466 cherenkov radiation Effects 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- SBNOTUDDIXOFSN-UHFFFAOYSA-N 1h-indole-2-carbaldehyde Chemical compound C1=CC=C2NC(C=O)=CC2=C1 SBNOTUDDIXOFSN-UHFFFAOYSA-N 0.000 description 1
- ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 1
- SRYYXVFONUYVLR-UHFFFAOYSA-N 2-[(6-nitro-1,3-benzodioxol-5-yl)methylidene]propanedinitrile Chemical compound C1=C(C=C(C#N)C#N)C([N+](=O)[O-])=CC2=C1OCO2 SRYYXVFONUYVLR-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMVSAKPRNWZCPG-UHFFFAOYSA-N 2-pyridin-4-ylacetonitrile Chemical compound N#CCC1=CC=NC=C1 BMVSAKPRNWZCPG-UHFFFAOYSA-N 0.000 description 1
- NRZWECORTTWSEF-UHFFFAOYSA-N 6-nitro-1,3-benzodioxole-5-carbaldehyde Chemical compound C1=C(C=O)C([N+](=O)[O-])=CC2=C1OCO2 NRZWECORTTWSEF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001479434 Agfa Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 244000278792 Calathea allouia Species 0.000 description 1
- 235000007487 Calathea allouia Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000005644 Wolff-Kishner reduction reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- QDYTUZCWBJRHKK-UHFFFAOYSA-N imidazole-4-methanol Chemical compound OCC1=CNC=N1 QDYTUZCWBJRHKK-UHFFFAOYSA-N 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 1
- NBKQRVSGHYZUOR-UHFFFAOYSA-N indoline-3-carbaldehyde Natural products C1=CC=C2C(C=O)CNC2=C1 NBKQRVSGHYZUOR-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QECIGCMPORCORE-UHFFFAOYSA-N phenanthrene-9-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC3=CC=CC=C3C2=C1 QECIGCMPORCORE-UHFFFAOYSA-N 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- BNHGNFYPZNDLAF-UHFFFAOYSA-N tricyanoaminopropene Chemical compound N#CCC(N)=C(C#N)C#N BNHGNFYPZNDLAF-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Heteroarylethenediyl or heteroarylethenediyl aryl compounds wherein the heteroaryl group can be mono- or bicyclic heteroaryl and the aryl group can be mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents, and pharmaceutical compositions comprising said compounds, and the use thereof for inhibiting cell proliferation in a patient suffering from such disorder.
Description
20~0~82 HETEROCYCLICETHENEDIYL COMPOUNDS WHICH
INHIBIT EGF RECEPTOR TYROSINE KINASE
FIELD OF THE INVENTION
This invention relates to the inhibition of cell proliferation. More specifically, this invention relates to the use of heterocyclicethenediyl compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTX~ inhibitors.
Normal cellular reproduction is believed to be triggered - by the exposure of the cellular sùbstrate to one or more growth factors, examples of which are insulin, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF).
Such growth Pact~rs are typically specific for corresponding growth factor receptors which are imbedded in and which penetrate through the cellular membrane. The initiation of cellular reproduction is believed to occur when a growth factor binds to the corresponding receptor on the external surface of the cellular membrane. This growth factor-receptor binding alters the chemical characteristics of that portion of the receptor which exists within the celI and which functions - as an enzyme to catalyze phosphorylation of either an
INHIBIT EGF RECEPTOR TYROSINE KINASE
FIELD OF THE INVENTION
This invention relates to the inhibition of cell proliferation. More specifically, this invention relates to the use of heterocyclicethenediyl compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTX~ inhibitors.
Normal cellular reproduction is believed to be triggered - by the exposure of the cellular sùbstrate to one or more growth factors, examples of which are insulin, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF).
Such growth Pact~rs are typically specific for corresponding growth factor receptors which are imbedded in and which penetrate through the cellular membrane. The initiation of cellular reproduction is believed to occur when a growth factor binds to the corresponding receptor on the external surface of the cellular membrane. This growth factor-receptor binding alters the chemical characteristics of that portion of the receptor which exists within the celI and which functions - as an enzyme to catalyze phosphorylation of either an
2 ~ g ~S ~ 2 PCT/US9l/025c~
intracellular substrate or the receptor itself, the latter being referred to as autophosphorylation. Examples of such phosphorylation enzymes include tyrosine kinases, which catalyze phosphorylation of tyrosine amino acid residues of substrate proteins.
Many diseased states are characterized by the uncontrolled reproduction of cells. These diseased states involve a variety of cell types and include disorders such as leukemia, cancer, psoriasis, atherosclerosis and restenosis injuries. The inhibition of tyrosine kinase is believed to have utility in the control of uncontrolled cellular reproduction, i.e., cellular proliferative disorders.
Initiation of autophosphorylation, i.e., phosphorylation of the growth factor receptor itself, and of the phosphorylation of a ~ost of intracellular substrates are some of the biochemical events which are involved in mitogenesis and cell proliferation. Autophosphorylation of the insulin receptor and phosphorylation of substrate proteins by other receptors are the earliest identifiable biochemical hormonal Z0 responses.
Elimination of the protein tyrosine kinase (PTK) activity of the insulin receptor and of th~ epidermal growth factor (EGF) receptor by site-directed mutagenesis of the cellular genetic material which is responsible for generation of insulin and E~F results in the complete elimination of the receptors' biological activity. This is not particularly desirable because insulin is needed by the body to perform other biological functions which are not related to cell proliferation. Accordingly, compounds which inhiblt thé PTK
portion of the EGF receptor at concentrations less than the concentrations needed to inhibit the PTK portion of the insulin receptor could provide valuable agents for selective treatment of cell proliferation disarders.
WO91/16305 2 ~ PCT/US91/02597 REPORTED DEVELOPMENTS
The use of furanal malononitri:Le and thienylidene malononitrile compounds as tumor growth inhibitors is disclosed in Gal et al., Studies on the Biological Action of Malononitriles. I. The Effect of Substituted Malononitriles on the Growth of Transplanted Tumors in Mice, Cancer Research, ~2:565-72, 1952.
It has been reported that the most potent inhibitors of EGF receptors inhibit EGF-induced proliferation of A431/clone ~0 15 cells with little or no effect on the proliferation of such cells when induced by other growth factors. It has been reported also that erbstatin inhibits the autophosphorylation of the EGF receptor in membranes of A431 cells. Low concentrations of erbstatin are required to inhibit EGF
receptor autophosphorylation, whereas much higher concentra-tions of erbstatin are required to inhibit cyclic adenosine
intracellular substrate or the receptor itself, the latter being referred to as autophosphorylation. Examples of such phosphorylation enzymes include tyrosine kinases, which catalyze phosphorylation of tyrosine amino acid residues of substrate proteins.
Many diseased states are characterized by the uncontrolled reproduction of cells. These diseased states involve a variety of cell types and include disorders such as leukemia, cancer, psoriasis, atherosclerosis and restenosis injuries. The inhibition of tyrosine kinase is believed to have utility in the control of uncontrolled cellular reproduction, i.e., cellular proliferative disorders.
Initiation of autophosphorylation, i.e., phosphorylation of the growth factor receptor itself, and of the phosphorylation of a ~ost of intracellular substrates are some of the biochemical events which are involved in mitogenesis and cell proliferation. Autophosphorylation of the insulin receptor and phosphorylation of substrate proteins by other receptors are the earliest identifiable biochemical hormonal Z0 responses.
Elimination of the protein tyrosine kinase (PTK) activity of the insulin receptor and of th~ epidermal growth factor (EGF) receptor by site-directed mutagenesis of the cellular genetic material which is responsible for generation of insulin and E~F results in the complete elimination of the receptors' biological activity. This is not particularly desirable because insulin is needed by the body to perform other biological functions which are not related to cell proliferation. Accordingly, compounds which inhiblt thé PTK
portion of the EGF receptor at concentrations less than the concentrations needed to inhibit the PTK portion of the insulin receptor could provide valuable agents for selective treatment of cell proliferation disarders.
WO91/16305 2 ~ PCT/US91/02597 REPORTED DEVELOPMENTS
The use of furanal malononitri:Le and thienylidene malononitrile compounds as tumor growth inhibitors is disclosed in Gal et al., Studies on the Biological Action of Malononitriles. I. The Effect of Substituted Malononitriles on the Growth of Transplanted Tumors in Mice, Cancer Research, ~2:565-72, 1952.
It has been reported that the most potent inhibitors of EGF receptors inhibit EGF-induced proliferation of A431/clone ~0 15 cells with little or no effect on the proliferation of such cells when induced by other growth factors. It has been reported also that erbstatin inhibits the autophosphorylation of the EGF receptor in membranes of A431 cells. Low concentrations of erbstatin are required to inhibit EGF
receptor autophosphorylation, whereas much higher concentra-tions of erbstatin are required to inhibit cyclic adenosine
3',5'-monophosphate (cAMP)-dependent protein kinase.
SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided a method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a heteroarylethenPdiyl or a heteroarylethenediyl aryl compound, or a pharmaceutically acceptable salt thereof, exhibiting protein tyrosine kinase inhibition activity, wherein the heteroaryl group can be mono-or bicyclic heteroaryl and the aryl group can be mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, provided that the heteroaryl ~roup is not furyl or thienyl when the ethenediyl ~roup has geminal cyano substituents.
Another aspect of the present invention relates to pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of the aforementioned type of compound.
WO91/16305 2 ~ 8 ~ ~ ~ 2 PCT/US91/025;~
Still another aspect of the present invention relates to novel compounds of the aforementioned type.
Compounds described by Formula I below constitute a class of the aforementioned heteroarylethenediyl or heteroaryl-ethenediyl aryl compounds for use in the practice of thepresent invention:
C=C
W R~
wherein:
W is a heteroaryl ring system having an about 5- to about 7-membered monocyclic ring including l or 2 N, O or S
atoms, or an about 8- to about 12-membered bicyclic ring including l to about 4 N, O or S atoms, said ring system optionally-substituted with one to about three R~ groups;
Rl is alkyl, -CN, -CONRR, -CSNRR or -COOR;
R is hydrogen, alkyl or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR, -CH=C~CN) 2 -C(NH2)=~(CN)2~ .
_co,~, -Co~
S~
~CO ~ ¦ or-an about 9- to ahout 11-membered bicyclic aryl carbocyclic ring system or an about 12- to about 15-membered tricyclic aryl carbocyclic ring system, said ring system optionally substituted with one to about three R4 groups;
- R3 is hydrogen, alkyl, -CN, -CH2CN, -CONRR, -CSNRR, -COOR
or -CH=C(CN)CONH2;
each ~ -is independently alkyl, hydroxy, alkoxy, halo, amino, mono- and di-alkylamino, acetylamino, alkylthio, -CN, -CF3, nitro, -COOR, -CONRR, -CSNRR, -CHO, -C~=CHCOOH, -NHCO(CH2)2COOH or morpholino;
R5 is amino, -CONH2, -(CH2)~-NHCO-C-CH ~ ~3 -(CH) ~ R,7) ~3 0 each R6 is independently hydrogen, alkyl, hydroxy, alkoxy or halo;
each R~ is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0 to about 6; and m is 1 to about 7;
with the proviso that when both R~ and R2 are -CN, W is not furyl or thienyl.
WO9l/1~305 PCT/US91/025~`
2 ~ 8 0 3 8 2 Compounds within the scope of the present invention have also a specific affinity toward the substrate site of the tyrosine kinase domain of EGF receptors, inhibit EGF receptor kinase more than they inhibit PDGF receptor kinase and also effectively inhibit EGF-dependent autophosphorylation of the receptor.
DETAILED DESCRIPTION OF_THE INVENTION
As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Alkyl" means a saturated aliphatic hydrocarbon whlch may be either straight- or branch-chained containing from about 1 to about 6 carbon atoms.
"Lower alXyl" means an alkyl group as above, having 1 to about 4 carbon atoms which may be straight- or branch-chained such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.
"Alkoxy" means an alkyl-oxy group in which "alkyl" is as previously described. Lower alkoxy groups are preferred.
Exemplary groups include methoxy, ethoxy, n-propoxy, i-propoxy and n-butoxy.
"Aryl" means an unsaturated or partially unsaturated ring system. Preferred aryl groups are pyridyl and indolyl.
"Acyl" means an organic radical derived from an organic acid, a carboxylic acid, by the removal of its acid hydroxyl group. Preferrecl acyl groups are lower alkyl carboxylic acid groups such as acetyl and propionyl. Benzoyl is also preferred.
"Halo" means a halogen. Preferred halogens include chloride, bromide and fluoride.
` WO91/16305 2 ~ 8 0 ~ ~ 2 PCT/US91/02597 Preferred aralkyl groups are benzyl and phenethyl.
It is believed that therapeutically useful PTK inhibiting compounds should be competitive with the substrate of EGF
receptor tyrosine kinase (EGFRK) and not with adenosine triphosphate (ATP)~ The PTX inhibitors guercetin and genistein, which compete with ATP, inhibit other protein kinases and as a result are highly cytotoxic. As a test of selectivity, compounds which inhibit EGFRK better than they inhibit insulin receptor kinase ~IRK) and/or PDGF receptor kinase are of considerable value.
It is theorized that solubility of the compounds of the present invention both in water and in mildly hydrophobic solvents will enhance the probability that they traverse the cell membrane. Various insoluble compounds, however, have exhibited significant EGFRK inhibition in in vitro testing.
A preferred class of compounds useful in the practice of the present invention include those described by Formula I
where:
W is a 5- or 6-membered monocyclic aryl ring including l or 2 N, O or S atoms, or a 9- or l0-membered bicyclic aryl ring including l to 4 N, O or S atoms, said ring optionally substituted with one to about three R4 groups;
.
R~ is -CN, -CONRR, -CSNRR or -COCR;
R is hydrogen, alkyl, or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR or ~R7)~3 -CO~
R3 is hydrogen;
WO91/16305 2 ~ 3 2 8 PCT/US91/02S~:
each ~ is independently alkyl, hydroxy, alkoxy or halo;
R5 is amino, -CO~H2, s fN ~R~) ~3 -(CH2)~-NHCO-C=CH ~ or ~ ~ R7)~3 each ~ is independently hydrogen or alkyl;
each R7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0-4; and m is 2-6;
with the proviso that when both R~ and R2 are -CN, W is not furyl or thienyl.
The more preferred compounds of this invention lnclude those of Formula I where:
W is furyl, pyrrolyl, thienyl, thiazolyl, pyridyl, imidazolyl, isoimidazolyl, pyridazinyl, pyrimdinyl, benzofuranyl, indolyl, indolinyl, indolinonyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromenyl, l,3-benzodioxolyl or 2,3-dihydro-l,4-benzodioxinyl.
The most preferred compounds are described by Formula I
where:
" WO91/16305 2 0 8 0 ~ g 2 PCT/~S91/02597 W is pyridyl, indolyl, imidazolyl, benzothiazolyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl;
R~ is -CN, -CONRR, -CSNRR or -COOR;
is hydrogen, alkyl, or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR or (R7)~3 -CO~
R3 is hydrogen;
each ~ is independently lower alkyl, hydroxy, lower alkoxy or halo;
-(CH2) -NHCO-C=CH ~ R~)~3 -(CH2) ~ R7)~3 each R~ is independently lower alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0-4; and m is 2-6.
Compounds of this invention may be useful in the form of the free base, in the form of salts and as a hydrate. A11 forms are within the scope of the invention. Acid addition W091/16305 2 ~ 8 ~ ~ 8 ~ PCT/~S9t/025~-salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base~, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not vitiated by side effects ascribable to the anions.
lo Although pharmaceutically acceptable salts of said basic compound are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt per se is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification and identification, or when it is used as an intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.
Pharmaceutically acceptable salts within the scope of the invention include those derived from the following acids:
mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like.
~ he correspondin~ acid addition salts comprise the following: hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartarate, methanesulfonate, ethanesulfonats, benæenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.
The acid addition salts of the compounds of this invention are prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by ` WO91/16305 ~ S 2 PCT/US91/02597 evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
Compounds useful in the practice of this invention can be prepared by known methods, for example, Xnoevenagel condensation reactions such as those disclosed in ~.s. Patent No. 3,149,148.
Co~pounds of this invention may be prepared by the following reaction sequence:
W-C(R3)0 + R~-CH2-R2 > C=C
W R~
Knoevenagel condensation of a heterocyclic aldehyde of formula W in a polar media with an active methylene compound of the formula R,CH2R2 in the presence of ammonia or amines such as piperidine and raised heat results in the products of this invention. When substitution of the R3 group is desired, the corresponding ketone starting material is used. Reaction temperatures in the range of 25~C to reflux and reaction times vary depending on the materials being used in the condensation.
Compounds of this invention are either comme~cially available, known in the literature or can be made by known procedures.
- Various R, R~, R2, R3, R4, R5, ~ and R7 substituents on the hetero ring or chain can be present in the starting compound or added after formation of the condensation product by methods known in the art for substitution or conversion on one group to another. If the substituents ~hemselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety of protecting groups known in the art, may be employed. Examples ~ J~
WO91/16305 PCT/US91/025a:
of many of these possible groups may be found in "Protective Groups in Organic Synthesis" by T. W. Green, John Wiley and Sons, 1981. For example, nitro groups can be added to the aromatic ring by nitration and the nitro group converted to other groups, such as amino by reduction, and halo by diazotization of the amino group and replacement of the diazo group. Acyl groups can be substituted onto the aryl groups by Friedel Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction. Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers. Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product.
Compounds within the scope of this invention exhibit significant activity as protein tyrosine kinase inhibitors and possess therapeutic value as cellular antiproliferative ayents for the treatment of certain conditions including, for example, psoriasis and restenosis injuries. It is expected that the invention will be particularly applicable to the treatment of atherosclerosis. With regard to the treatment of some~conditions, for example, atherosclerosis, certain people may be identified as being at high risk, for example, due to genetic, environmental or historical factors. Compounds within the scope of the present invention can be used in preventin~ or delaying the occurrence or reoccurrence of such conditions or otherwise treating the condition.
Compounds of the present invention can be administered to a mammalian host in a variety of forms adapted to the chosen route of administration, i.e., orally, or parenterally.
WO91/1630~ 2 0 ~ O .~ ~ ~ PCT/US91/02597 Parenteral administration in this respect includes administration by the following routesO intravenous, - intramusc~lar, subcutaneous, intr~ocular, intrasynovial, transepithelial including transdermal, ophthalmic, sublingual and buccal; topically including ophthalmic, dermal, ocular, rectal and nasal inhalation via insufflation and aerosol and rectal systemic.
The active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. SUG~ compositions and preparations should contain at least 0.1~ of active compound. The percentage of the compositions and preparations may, of cour~e, be varied and may conveniently be between Z0 about 2 to about 6% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 1 and 1000 mg of active compound.
The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starchJ alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other WO91/1630~ 2 ~ g ~ PCT/US91/025~ l !
materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both.
A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.
The active compound may also be administered parenterally or intraperitoneally. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It may be stable under the conditions of manufacture and storage and must be preserved aqainst the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of -` WO91/16305 2 0 8 0 S ~ ~ PCT/US91/02597 microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
The therapeutic compounds of this invention may be administered to a mammal alsne or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.
The dosage of the present therapeutic agents which will be most suitable for prophylaxis or treatment wiil vary with the form of administration, the particular compound chosen and the physiological characteristics of the particular patient under treatment. Generally, small dosages will be used initially and if necessary, will be increased by small increments until the optimum effect under the circumstances is WO~1/1630S 2 0 ~ 03 8 ~ PCT/US91/025~
, reached. The therapeutic human dosage, based on physiological studies using rats, will generally be from about 0.01 mg to about 100 mg/kg of body weight per day or from about 0.4 mg to about 10 g or and higher although it may ~e administered in several different dosage units from once to several times a day. Oral administration requires higher dosages.
EXAMPLES
Embodiments of the present invention are described in the following non-limiting examples which include a description of pharmacological test procedures believed to correlate to therapeutic activity in humans and other animals. Examples 1-11 below are illustrative of compounds within the scope of the present invention. Examples 1-5 illustrate various unsubstituted heteroaryl malononitriles, i.e., Rl and R2 are each -CN and the other R substituents are all hydrogen.
Example 6 illustrates a compound wherein R~ is -CN,:R2 is -C(NH2~=C(CN)2, R3 is hydrogen and there are no ~a substituents.
Example 7 illustrates a nitro-substituted heteroaryl malononitrile, i.e., R~ and R2 are each -CN, R3 is hydrogen and R4 is nitro. Example 8 illustrates a diheteroarylethenediyl compound, i.e., R~ is -CN, R2 is pyridyl and the other R
substituents are all hydrogen. Example g illustrates a heteroarylethenediyl carbocyclic compound, i.e., R~ is hydrogen, R2 is phenanthryl, R3 is -CN and there are no R~
substituents. Examples 10 and 11 illustrate heteroarylethenediyl aryl compounds, i.e., R~ is -CN,. R2 is 3,4-dihydroxybenzoyl and R3 is -H.
.
Example 1 2-Imidazolidene malononitrile To 0.4 g (4 mmol~ 2-formylimidazole (Aldrich) and 0.5 g (4.5 mmol) malononitrile in 15 ml ethanol was added 30 mg ~-alanine. The reaction was refluxed for one hour, evaporated to dryness and the dark solid obtained was flash-chromatographed on silica gel (elution with CH2Cl2 to 3 WOg1~163~5 2 0 ~ ~ a ~ 2 PCT/~S9l/~25g7 ethanol) to give 0.2g (33% yield) of a yellow solid, m.p.
180C (decomposition~.
Example 2 5-Pvrazolidene malononitrile S (a) To CH2N2 (from 10 g diazald) in 50 ml ether was added 2.5 g (16.5 mmol) propyne acetal. After 3 days of refrigeration, 50 ml ethanol and 10 drops concentrated ~Cl were added and the reaction mixture was stirred for 15 minutes at room temperature, evaporated to dryness and triturated with CCl4 to give 90 mg of a formyl pyrazole, a light yellow solid.
(b) To 80 mg of the pyrazole from step (a) above and 70 mg malononitrile in 20 ml ethanol was added 20 mg ~-alanine and the reaction mixture was refluxed for 20 hours. Water was added and the reaction mixture was extracted with EtAc, evaporated and flash chromatographed to give 30 mg (25~ yield) of product, a yellow solid, m.p. lS4C.
Example 3
SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided a method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a heteroarylethenPdiyl or a heteroarylethenediyl aryl compound, or a pharmaceutically acceptable salt thereof, exhibiting protein tyrosine kinase inhibition activity, wherein the heteroaryl group can be mono-or bicyclic heteroaryl and the aryl group can be mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, provided that the heteroaryl ~roup is not furyl or thienyl when the ethenediyl ~roup has geminal cyano substituents.
Another aspect of the present invention relates to pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of the aforementioned type of compound.
WO91/16305 2 ~ 8 ~ ~ ~ 2 PCT/US91/025;~
Still another aspect of the present invention relates to novel compounds of the aforementioned type.
Compounds described by Formula I below constitute a class of the aforementioned heteroarylethenediyl or heteroaryl-ethenediyl aryl compounds for use in the practice of thepresent invention:
C=C
W R~
wherein:
W is a heteroaryl ring system having an about 5- to about 7-membered monocyclic ring including l or 2 N, O or S
atoms, or an about 8- to about 12-membered bicyclic ring including l to about 4 N, O or S atoms, said ring system optionally-substituted with one to about three R~ groups;
Rl is alkyl, -CN, -CONRR, -CSNRR or -COOR;
R is hydrogen, alkyl or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR, -CH=C~CN) 2 -C(NH2)=~(CN)2~ .
_co,~, -Co~
S~
~CO ~ ¦ or-an about 9- to ahout 11-membered bicyclic aryl carbocyclic ring system or an about 12- to about 15-membered tricyclic aryl carbocyclic ring system, said ring system optionally substituted with one to about three R4 groups;
- R3 is hydrogen, alkyl, -CN, -CH2CN, -CONRR, -CSNRR, -COOR
or -CH=C(CN)CONH2;
each ~ -is independently alkyl, hydroxy, alkoxy, halo, amino, mono- and di-alkylamino, acetylamino, alkylthio, -CN, -CF3, nitro, -COOR, -CONRR, -CSNRR, -CHO, -C~=CHCOOH, -NHCO(CH2)2COOH or morpholino;
R5 is amino, -CONH2, -(CH2)~-NHCO-C-CH ~ ~3 -(CH) ~ R,7) ~3 0 each R6 is independently hydrogen, alkyl, hydroxy, alkoxy or halo;
each R~ is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0 to about 6; and m is 1 to about 7;
with the proviso that when both R~ and R2 are -CN, W is not furyl or thienyl.
WO9l/1~305 PCT/US91/025~`
2 ~ 8 0 3 8 2 Compounds within the scope of the present invention have also a specific affinity toward the substrate site of the tyrosine kinase domain of EGF receptors, inhibit EGF receptor kinase more than they inhibit PDGF receptor kinase and also effectively inhibit EGF-dependent autophosphorylation of the receptor.
DETAILED DESCRIPTION OF_THE INVENTION
As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Alkyl" means a saturated aliphatic hydrocarbon whlch may be either straight- or branch-chained containing from about 1 to about 6 carbon atoms.
"Lower alXyl" means an alkyl group as above, having 1 to about 4 carbon atoms which may be straight- or branch-chained such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.
"Alkoxy" means an alkyl-oxy group in which "alkyl" is as previously described. Lower alkoxy groups are preferred.
Exemplary groups include methoxy, ethoxy, n-propoxy, i-propoxy and n-butoxy.
"Aryl" means an unsaturated or partially unsaturated ring system. Preferred aryl groups are pyridyl and indolyl.
"Acyl" means an organic radical derived from an organic acid, a carboxylic acid, by the removal of its acid hydroxyl group. Preferrecl acyl groups are lower alkyl carboxylic acid groups such as acetyl and propionyl. Benzoyl is also preferred.
"Halo" means a halogen. Preferred halogens include chloride, bromide and fluoride.
` WO91/16305 2 ~ 8 0 ~ ~ 2 PCT/US91/02597 Preferred aralkyl groups are benzyl and phenethyl.
It is believed that therapeutically useful PTK inhibiting compounds should be competitive with the substrate of EGF
receptor tyrosine kinase (EGFRK) and not with adenosine triphosphate (ATP)~ The PTX inhibitors guercetin and genistein, which compete with ATP, inhibit other protein kinases and as a result are highly cytotoxic. As a test of selectivity, compounds which inhibit EGFRK better than they inhibit insulin receptor kinase ~IRK) and/or PDGF receptor kinase are of considerable value.
It is theorized that solubility of the compounds of the present invention both in water and in mildly hydrophobic solvents will enhance the probability that they traverse the cell membrane. Various insoluble compounds, however, have exhibited significant EGFRK inhibition in in vitro testing.
A preferred class of compounds useful in the practice of the present invention include those described by Formula I
where:
W is a 5- or 6-membered monocyclic aryl ring including l or 2 N, O or S atoms, or a 9- or l0-membered bicyclic aryl ring including l to 4 N, O or S atoms, said ring optionally substituted with one to about three R4 groups;
.
R~ is -CN, -CONRR, -CSNRR or -COCR;
R is hydrogen, alkyl, or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR or ~R7)~3 -CO~
R3 is hydrogen;
WO91/16305 2 ~ 3 2 8 PCT/US91/02S~:
each ~ is independently alkyl, hydroxy, alkoxy or halo;
R5 is amino, -CO~H2, s fN ~R~) ~3 -(CH2)~-NHCO-C=CH ~ or ~ ~ R7)~3 each ~ is independently hydrogen or alkyl;
each R7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0-4; and m is 2-6;
with the proviso that when both R~ and R2 are -CN, W is not furyl or thienyl.
The more preferred compounds of this invention lnclude those of Formula I where:
W is furyl, pyrrolyl, thienyl, thiazolyl, pyridyl, imidazolyl, isoimidazolyl, pyridazinyl, pyrimdinyl, benzofuranyl, indolyl, indolinyl, indolinonyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromenyl, l,3-benzodioxolyl or 2,3-dihydro-l,4-benzodioxinyl.
The most preferred compounds are described by Formula I
where:
" WO91/16305 2 0 8 0 ~ g 2 PCT/~S91/02597 W is pyridyl, indolyl, imidazolyl, benzothiazolyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl;
R~ is -CN, -CONRR, -CSNRR or -COOR;
is hydrogen, alkyl, or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR or (R7)~3 -CO~
R3 is hydrogen;
each ~ is independently lower alkyl, hydroxy, lower alkoxy or halo;
-(CH2) -NHCO-C=CH ~ R~)~3 -(CH2) ~ R7)~3 each R~ is independently lower alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0-4; and m is 2-6.
Compounds of this invention may be useful in the form of the free base, in the form of salts and as a hydrate. A11 forms are within the scope of the invention. Acid addition W091/16305 2 ~ 8 ~ ~ 8 ~ PCT/~S9t/025~-salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base~, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not vitiated by side effects ascribable to the anions.
lo Although pharmaceutically acceptable salts of said basic compound are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt per se is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification and identification, or when it is used as an intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.
Pharmaceutically acceptable salts within the scope of the invention include those derived from the following acids:
mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like.
~ he correspondin~ acid addition salts comprise the following: hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartarate, methanesulfonate, ethanesulfonats, benæenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.
The acid addition salts of the compounds of this invention are prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by ` WO91/16305 ~ S 2 PCT/US91/02597 evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
Compounds useful in the practice of this invention can be prepared by known methods, for example, Xnoevenagel condensation reactions such as those disclosed in ~.s. Patent No. 3,149,148.
Co~pounds of this invention may be prepared by the following reaction sequence:
W-C(R3)0 + R~-CH2-R2 > C=C
W R~
Knoevenagel condensation of a heterocyclic aldehyde of formula W in a polar media with an active methylene compound of the formula R,CH2R2 in the presence of ammonia or amines such as piperidine and raised heat results in the products of this invention. When substitution of the R3 group is desired, the corresponding ketone starting material is used. Reaction temperatures in the range of 25~C to reflux and reaction times vary depending on the materials being used in the condensation.
Compounds of this invention are either comme~cially available, known in the literature or can be made by known procedures.
- Various R, R~, R2, R3, R4, R5, ~ and R7 substituents on the hetero ring or chain can be present in the starting compound or added after formation of the condensation product by methods known in the art for substitution or conversion on one group to another. If the substituents ~hemselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety of protecting groups known in the art, may be employed. Examples ~ J~
WO91/16305 PCT/US91/025a:
of many of these possible groups may be found in "Protective Groups in Organic Synthesis" by T. W. Green, John Wiley and Sons, 1981. For example, nitro groups can be added to the aromatic ring by nitration and the nitro group converted to other groups, such as amino by reduction, and halo by diazotization of the amino group and replacement of the diazo group. Acyl groups can be substituted onto the aryl groups by Friedel Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction. Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers. Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product.
Compounds within the scope of this invention exhibit significant activity as protein tyrosine kinase inhibitors and possess therapeutic value as cellular antiproliferative ayents for the treatment of certain conditions including, for example, psoriasis and restenosis injuries. It is expected that the invention will be particularly applicable to the treatment of atherosclerosis. With regard to the treatment of some~conditions, for example, atherosclerosis, certain people may be identified as being at high risk, for example, due to genetic, environmental or historical factors. Compounds within the scope of the present invention can be used in preventin~ or delaying the occurrence or reoccurrence of such conditions or otherwise treating the condition.
Compounds of the present invention can be administered to a mammalian host in a variety of forms adapted to the chosen route of administration, i.e., orally, or parenterally.
WO91/1630~ 2 0 ~ O .~ ~ ~ PCT/US91/02597 Parenteral administration in this respect includes administration by the following routesO intravenous, - intramusc~lar, subcutaneous, intr~ocular, intrasynovial, transepithelial including transdermal, ophthalmic, sublingual and buccal; topically including ophthalmic, dermal, ocular, rectal and nasal inhalation via insufflation and aerosol and rectal systemic.
The active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. SUG~ compositions and preparations should contain at least 0.1~ of active compound. The percentage of the compositions and preparations may, of cour~e, be varied and may conveniently be between Z0 about 2 to about 6% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 1 and 1000 mg of active compound.
The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starchJ alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other WO91/1630~ 2 ~ g ~ PCT/US91/025~ l !
materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both.
A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.
The active compound may also be administered parenterally or intraperitoneally. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It may be stable under the conditions of manufacture and storage and must be preserved aqainst the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of -` WO91/16305 2 0 8 0 S ~ ~ PCT/US91/02597 microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
The therapeutic compounds of this invention may be administered to a mammal alsne or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.
The dosage of the present therapeutic agents which will be most suitable for prophylaxis or treatment wiil vary with the form of administration, the particular compound chosen and the physiological characteristics of the particular patient under treatment. Generally, small dosages will be used initially and if necessary, will be increased by small increments until the optimum effect under the circumstances is WO~1/1630S 2 0 ~ 03 8 ~ PCT/US91/025~
, reached. The therapeutic human dosage, based on physiological studies using rats, will generally be from about 0.01 mg to about 100 mg/kg of body weight per day or from about 0.4 mg to about 10 g or and higher although it may ~e administered in several different dosage units from once to several times a day. Oral administration requires higher dosages.
EXAMPLES
Embodiments of the present invention are described in the following non-limiting examples which include a description of pharmacological test procedures believed to correlate to therapeutic activity in humans and other animals. Examples 1-11 below are illustrative of compounds within the scope of the present invention. Examples 1-5 illustrate various unsubstituted heteroaryl malononitriles, i.e., Rl and R2 are each -CN and the other R substituents are all hydrogen.
Example 6 illustrates a compound wherein R~ is -CN,:R2 is -C(NH2~=C(CN)2, R3 is hydrogen and there are no ~a substituents.
Example 7 illustrates a nitro-substituted heteroaryl malononitrile, i.e., R~ and R2 are each -CN, R3 is hydrogen and R4 is nitro. Example 8 illustrates a diheteroarylethenediyl compound, i.e., R~ is -CN, R2 is pyridyl and the other R
substituents are all hydrogen. Example g illustrates a heteroarylethenediyl carbocyclic compound, i.e., R~ is hydrogen, R2 is phenanthryl, R3 is -CN and there are no R~
substituents. Examples 10 and 11 illustrate heteroarylethenediyl aryl compounds, i.e., R~ is -CN,. R2 is 3,4-dihydroxybenzoyl and R3 is -H.
.
Example 1 2-Imidazolidene malononitrile To 0.4 g (4 mmol~ 2-formylimidazole (Aldrich) and 0.5 g (4.5 mmol) malononitrile in 15 ml ethanol was added 30 mg ~-alanine. The reaction was refluxed for one hour, evaporated to dryness and the dark solid obtained was flash-chromatographed on silica gel (elution with CH2Cl2 to 3 WOg1~163~5 2 0 ~ ~ a ~ 2 PCT/~S9l/~25g7 ethanol) to give 0.2g (33% yield) of a yellow solid, m.p.
180C (decomposition~.
Example 2 5-Pvrazolidene malononitrile S (a) To CH2N2 (from 10 g diazald) in 50 ml ether was added 2.5 g (16.5 mmol) propyne acetal. After 3 days of refrigeration, 50 ml ethanol and 10 drops concentrated ~Cl were added and the reaction mixture was stirred for 15 minutes at room temperature, evaporated to dryness and triturated with CCl4 to give 90 mg of a formyl pyrazole, a light yellow solid.
(b) To 80 mg of the pyrazole from step (a) above and 70 mg malononitrile in 20 ml ethanol was added 20 mg ~-alanine and the reaction mixture was refluxed for 20 hours. Water was added and the reaction mixture was extracted with EtAc, evaporated and flash chromatographed to give 30 mg (25~ yield) of product, a yellow solid, m.p. lS4C.
Example 3
4-Imidazol~idene malononitrile 4-Hydroxymethyl imidazole (Aldrich) was oxidized with HNO3 and the reaction mixture was evaporated to dryness to give 0.5 g of a light brown solid, to which, in 10 ml ethanol and 2 ml H20, was added 0.45 g (6.8 mmol) malononitrile and 50 mg ~-alanine. The reaction mixture was refluxed for 1 hour, evaporated to dryness and flash chromatographed. The second fracti~n yielded 20 mg of product as a yellow solid, m.p.
176C.
Exam~le 4 l-Indolinidene malononitrile Indoline, 0.8 g (6.7 mmol) and 0.8 g ~6.7 mmol) ethoxymethylene nialononitrile in 30 ml CH3CN were stirred for 30 minutes at room temperature and the precipitate was filtered off to give 0.78 g (51% yield) of product as a pale yellow solid, m.p. 228C.
wO91/16305 2 ~ 2 PCT/US91/025~^
Exam~le 5
176C.
Exam~le 4 l-Indolinidene malononitrile Indoline, 0.8 g (6.7 mmol) and 0.8 g ~6.7 mmol) ethoxymethylene nialononitrile in 30 ml CH3CN were stirred for 30 minutes at room temperature and the precipitate was filtered off to give 0.78 g (51% yield) of product as a pale yellow solid, m.p. 228C.
wO91/16305 2 ~ 2 PCT/US91/025~^
Exam~le 5
5-Indolidene malononitrile To 150 mg (1 mmol) 5~formyl indole and 80 mg (1.2 mmol) malononitrile in 10 ml ethanol was added 1 drop piperidine.
The reaction mixture was refluxed ~or 2.5 hours, H20 was added, the mixture cooled and filtered to give 140 mg (70~ yield) of product as a yellow solid, m.p. 225 ~C.
Example 6 1,1 3-Tricvano-2-amino-4-f5-indole~butadiene To 0.29 g (2 mmol) 5-formylindole and 0.28 g (2.1 mmol) malononitrile dimer in 10 ml ethanol was added 30 mg ~-alanine. The reaction mixture was refluxed for 4 hours, cooled, filtered, washed with H20 and ethanol and dried to give 0.16 g (31% yield) of product as a yellow-orange solid, m.p.
242C.
Example 7 3,4-Methylenedioxy-6-nitrobenzylidene malononitrile 1 g (5.1 mmol) 3,4-Methylenedioxy-6-nitrobenzaldehyde, 0.4 g S6 mmol) malononitrile and 0.2 g ~-alanine in 30 ml ethanol were stirred 16 hours at room temperature. 50 ml H20 was added. Filtering gave 1 g, (80% yield) of a bright yellow solid, m.p. 104C.
Example 8 Following the procedures of example 7 above, 2-(2-pyridyl~-3-[3,4-(methylenedioxy)phenyl]-2-propenenitrile was prepared, m.p. 153--55C.
Exam~le 9 2-(4-Pyridyl~-3-~9-Dhenanthryl)-2-proeenenitrile To a solution of 0.5 g (2.43 mmol) phenanthrene-9-carboxaldehyde in 40 ml absolute ethanol was added 0.375 g (2.43 mmol) 4-pyridylacetonitrile-~cl and 0.5 ml piperidine, and the reaction mixture was stirred and heated to reflux for 2 hours, at which time a yellow precipitate had formed. The ~ ` WO 91/16305 2 0 ~ O ~ 8 2 PCT/US91/02~97 reaction mixture was heated to reflux for an additional 2 hours, cooled to room temperature, and the solvent was partially evaporated. The mixture was partitioned between CH2Cl2 and H2O, washed with 5% NaHC03, dried over anhydrous Na2SO4, filtered, concentrated to give a yellow solid which was then flash chromatographed on silica gel. The material was loaded onto the column with CH2Cl2 and eluted with EtOAc:hexan~
~ to give 0.328 g (44% yield) of product as an amorphous yellow solid, m.p. 20Ç-208.
Example 10 2-(3l4-Dihydroxybenzoyl)-3-(5-indolYl~-2-propenenitrile 5-Formyl indole (145 mg, 1 mmole), 3,4-dihydroxy-benzoylacetonitrile (177 mg, 1 mmole) and ~-alanine (30 mg) in 30 ml ethanol were refluxed for 3 hours. Water was added and the reaction mixture was extracted with EtOAc. The organic layer was concentrated and the resulting oily residue was purified by chromatography on silica gel to give 86 mg (31%) of the title compound as an orange solid, m.p. 185C.
Example ll 2-~3.4-Dihydroxybenzovl)-3-(3-indolyl)-2-~ropenenitrile 3-Formyl indole (105 mg, 0.7 mmole~, 3,4-dihydroxy-benzoylacetonitrile (130 mg, 0.7 mmole) and B-alanine (20 mg3 in 30 ml ethanol were refluxed for 5 hours. Water was added and the reaction mixture was extracted with EtOAc. The organic layer was concentrated and the resulting oily solid was triturated with CH2Cl2 to give 160 mg (72%) of the title compound as an orange solid, m.p. 228C.
Compounds of this invention are subjected to various biological tests~ the results of which correlate to useful cellular antiproliferative activity. These tests are useful in dPtermining EGF receptor kinase, PDGF receptor kinase and insulin receptor kinase inhibition activities of the compounds disclosed herein.
WO91/16305 2 ~ 8 ~ ~ 8 2 PCT/US91/025~
~GF-Receptor Purification `
~GF-receptor purification is based on the procedure of Yarden and Schlessinger. A431 cells are grown in 80 cm2 -bottles to confluency (2 x 107 cells per bottle). The cells are washed twice with PBS and-harvested with PBS containing l.0 mmol EDTA (l hour at 37C), and centrifuged at 600g for lO
minutes. The cells are solubilized in l ml per 2 x 107 cells of cold solubilization buffer (50 mmol ~epes buffer, p~ 7.6, 1% Triton X-lO0, 150 mmol NaCl, 5 mmol EGTA, 1 mmol PMSF, 50 ~g/ml aprotinin, 25 mmol benzamidine, 5 ~g/ml leupeptic, and - lO ~g/ml soybean trypsin inhi~itor) for 20 minutes at 4C.
After centrifugation at lOOOOOg for 30 minutes, the supernatant is loaded onto a WGA-agarose column (lO0 ~l of packed resin per 2 x 107 cells) and shaken for 2 hours at 4OC.
The unabsorbed material is removed and the resin washed twice with HTN buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-lO0, 150 mmol NaCl), twice with HTN buffer containing l M NaCl, and twice with HTNG buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-100, 150 mmol NaCl, and lO~ glycerol). The EGF receptor is eluted ba~tchwise with HTNG buffer containing 0.5 M N-acetyl-D-glucosamine (200 ~l per 2 x 107 cells). The eluted material is stored in aliquots at -70C and diluted before use with TMTNG
buffer (50 mmol Tris-Mes buffer, pH 7.6, O.l~ Triton X-lO0, 150 mmol NaCl, 10% glycerol).
EGFR Kinase Catalyzed Phosphorylation of PolyLGAT! and its Inhibition WGA-purified EGFR (0.25 ~g/assay) is preactivated with EGF (0.85 ~M) in 50 mmol Tris-Mes buffer, pH 7.6 for 20 minutes at 4C. The assay is initiated by addition of a mixture which contains Mg(Ac)2 (60 mmol), [~-32P]ATP (125 ~M, 2- ;
5 ~Ci/assay), poly(GAT) (0.0625 mg/ml, 0.125 mg/ml, 0.25 mg/ml), and six concentrations of inhibitor in duplicates.
The temperature of the assay is 22C and the production of phosphorylated copolymer is found to be linear up to 20 minutes. The PTK inhibitors tested are solubilized in water or a mixture of ethanol and water such that the final WO91/16305 2 ~ 8 2 Pcr/us9l/o2597 concentration of ethanol does not exceed 4% in the assay. Up to 4% ethanol in the assay has no effect on the EGFR kinase activity. The concentration of EGF in the assay is 300 nM in a final volume of 40 ~ fter 5, lO or 20 minutes, aliquots of 25 ~l are applied onto Whatman 3-mm paper cuttings, which are then soaked in cold 10% TCA cont:aining O.Ol M sodium pyrophosphate. After being washed overnight at 4C, the paper cuttings are dried and counted, measuring 32p Cerenkov radiation. Concentration dependence on poly(GAT) was Michaelian with a Km ~ O.076 + 0.007 mg/ml or 0.069 + O.007 mmol i~ calculated per Glu5Ala3Tyr(GAT) unit. The EGF response for the poly(GAT) phosphorylation is graphed. The Km for ATP
in the assay was found to 2.9 ~M. Compounds of the examples were assayed for their ability to inhibit the EGF receptor tyrosine kinase activity. Table I below summarizes the results of this assay. "IC50" refers to the concentration (micromolar amounts) of inhibitor required to inhibit 50% of polyGAT phosphorylation under standard assay conditions.
PolyGAT concentration was equal to 2.3 Km values.
. .
Table I
Example IC5~l~M~
l 532
The reaction mixture was refluxed ~or 2.5 hours, H20 was added, the mixture cooled and filtered to give 140 mg (70~ yield) of product as a yellow solid, m.p. 225 ~C.
Example 6 1,1 3-Tricvano-2-amino-4-f5-indole~butadiene To 0.29 g (2 mmol) 5-formylindole and 0.28 g (2.1 mmol) malononitrile dimer in 10 ml ethanol was added 30 mg ~-alanine. The reaction mixture was refluxed for 4 hours, cooled, filtered, washed with H20 and ethanol and dried to give 0.16 g (31% yield) of product as a yellow-orange solid, m.p.
242C.
Example 7 3,4-Methylenedioxy-6-nitrobenzylidene malononitrile 1 g (5.1 mmol) 3,4-Methylenedioxy-6-nitrobenzaldehyde, 0.4 g S6 mmol) malononitrile and 0.2 g ~-alanine in 30 ml ethanol were stirred 16 hours at room temperature. 50 ml H20 was added. Filtering gave 1 g, (80% yield) of a bright yellow solid, m.p. 104C.
Example 8 Following the procedures of example 7 above, 2-(2-pyridyl~-3-[3,4-(methylenedioxy)phenyl]-2-propenenitrile was prepared, m.p. 153--55C.
Exam~le 9 2-(4-Pyridyl~-3-~9-Dhenanthryl)-2-proeenenitrile To a solution of 0.5 g (2.43 mmol) phenanthrene-9-carboxaldehyde in 40 ml absolute ethanol was added 0.375 g (2.43 mmol) 4-pyridylacetonitrile-~cl and 0.5 ml piperidine, and the reaction mixture was stirred and heated to reflux for 2 hours, at which time a yellow precipitate had formed. The ~ ` WO 91/16305 2 0 ~ O ~ 8 2 PCT/US91/02~97 reaction mixture was heated to reflux for an additional 2 hours, cooled to room temperature, and the solvent was partially evaporated. The mixture was partitioned between CH2Cl2 and H2O, washed with 5% NaHC03, dried over anhydrous Na2SO4, filtered, concentrated to give a yellow solid which was then flash chromatographed on silica gel. The material was loaded onto the column with CH2Cl2 and eluted with EtOAc:hexan~
~ to give 0.328 g (44% yield) of product as an amorphous yellow solid, m.p. 20Ç-208.
Example 10 2-(3l4-Dihydroxybenzoyl)-3-(5-indolYl~-2-propenenitrile 5-Formyl indole (145 mg, 1 mmole), 3,4-dihydroxy-benzoylacetonitrile (177 mg, 1 mmole) and ~-alanine (30 mg) in 30 ml ethanol were refluxed for 3 hours. Water was added and the reaction mixture was extracted with EtOAc. The organic layer was concentrated and the resulting oily residue was purified by chromatography on silica gel to give 86 mg (31%) of the title compound as an orange solid, m.p. 185C.
Example ll 2-~3.4-Dihydroxybenzovl)-3-(3-indolyl)-2-~ropenenitrile 3-Formyl indole (105 mg, 0.7 mmole~, 3,4-dihydroxy-benzoylacetonitrile (130 mg, 0.7 mmole) and B-alanine (20 mg3 in 30 ml ethanol were refluxed for 5 hours. Water was added and the reaction mixture was extracted with EtOAc. The organic layer was concentrated and the resulting oily solid was triturated with CH2Cl2 to give 160 mg (72%) of the title compound as an orange solid, m.p. 228C.
Compounds of this invention are subjected to various biological tests~ the results of which correlate to useful cellular antiproliferative activity. These tests are useful in dPtermining EGF receptor kinase, PDGF receptor kinase and insulin receptor kinase inhibition activities of the compounds disclosed herein.
WO91/16305 2 ~ 8 ~ ~ 8 2 PCT/US91/025~
~GF-Receptor Purification `
~GF-receptor purification is based on the procedure of Yarden and Schlessinger. A431 cells are grown in 80 cm2 -bottles to confluency (2 x 107 cells per bottle). The cells are washed twice with PBS and-harvested with PBS containing l.0 mmol EDTA (l hour at 37C), and centrifuged at 600g for lO
minutes. The cells are solubilized in l ml per 2 x 107 cells of cold solubilization buffer (50 mmol ~epes buffer, p~ 7.6, 1% Triton X-lO0, 150 mmol NaCl, 5 mmol EGTA, 1 mmol PMSF, 50 ~g/ml aprotinin, 25 mmol benzamidine, 5 ~g/ml leupeptic, and - lO ~g/ml soybean trypsin inhi~itor) for 20 minutes at 4C.
After centrifugation at lOOOOOg for 30 minutes, the supernatant is loaded onto a WGA-agarose column (lO0 ~l of packed resin per 2 x 107 cells) and shaken for 2 hours at 4OC.
The unabsorbed material is removed and the resin washed twice with HTN buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-lO0, 150 mmol NaCl), twice with HTN buffer containing l M NaCl, and twice with HTNG buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-100, 150 mmol NaCl, and lO~ glycerol). The EGF receptor is eluted ba~tchwise with HTNG buffer containing 0.5 M N-acetyl-D-glucosamine (200 ~l per 2 x 107 cells). The eluted material is stored in aliquots at -70C and diluted before use with TMTNG
buffer (50 mmol Tris-Mes buffer, pH 7.6, O.l~ Triton X-lO0, 150 mmol NaCl, 10% glycerol).
EGFR Kinase Catalyzed Phosphorylation of PolyLGAT! and its Inhibition WGA-purified EGFR (0.25 ~g/assay) is preactivated with EGF (0.85 ~M) in 50 mmol Tris-Mes buffer, pH 7.6 for 20 minutes at 4C. The assay is initiated by addition of a mixture which contains Mg(Ac)2 (60 mmol), [~-32P]ATP (125 ~M, 2- ;
5 ~Ci/assay), poly(GAT) (0.0625 mg/ml, 0.125 mg/ml, 0.25 mg/ml), and six concentrations of inhibitor in duplicates.
The temperature of the assay is 22C and the production of phosphorylated copolymer is found to be linear up to 20 minutes. The PTK inhibitors tested are solubilized in water or a mixture of ethanol and water such that the final WO91/16305 2 ~ 8 2 Pcr/us9l/o2597 concentration of ethanol does not exceed 4% in the assay. Up to 4% ethanol in the assay has no effect on the EGFR kinase activity. The concentration of EGF in the assay is 300 nM in a final volume of 40 ~ fter 5, lO or 20 minutes, aliquots of 25 ~l are applied onto Whatman 3-mm paper cuttings, which are then soaked in cold 10% TCA cont:aining O.Ol M sodium pyrophosphate. After being washed overnight at 4C, the paper cuttings are dried and counted, measuring 32p Cerenkov radiation. Concentration dependence on poly(GAT) was Michaelian with a Km ~ O.076 + 0.007 mg/ml or 0.069 + O.007 mmol i~ calculated per Glu5Ala3Tyr(GAT) unit. The EGF response for the poly(GAT) phosphorylation is graphed. The Km for ATP
in the assay was found to 2.9 ~M. Compounds of the examples were assayed for their ability to inhibit the EGF receptor tyrosine kinase activity. Table I below summarizes the results of this assay. "IC50" refers to the concentration (micromolar amounts) of inhibitor required to inhibit 50% of polyGAT phosphorylation under standard assay conditions.
PolyGAT concentration was equal to 2.3 Km values.
. .
Table I
Example IC5~l~M~
l 532
6 820 - The results of this assay indicate that the compounds of the present invention are effective in inhibiting substrate phosphorylation catalyzed by EGFRK.
Time_Dependence_oE EGF-Receptor Auto~hos~horYlation WGA-purified EGF receptor from A431 cells (0.5 ~g/assay) is activated with EGF (800 nM) for 20 minutes at 4C. The reaction is initiated by the addition of Mg(Ac)2 (60 mmol), Tris-~es buffer, pH 7.6 (50 mmol), and [32P]ATP (20 ~M, 5 ~Ci/assay). The reaction is conducted at either 4 or l5C and 2~3~2 WO91/16305 PCr/US91/02' terminated by addition of sodium dodecyl sulfate (SDS) sample buffer (10% glycerol, 50 mmol Tris, pH 6.8, 5~ ~-mercapto-ethanol, and 3% (SDS). The samples are run on a 8~ SDS
polyacrylamide gel (SDS-PAGE) (prepared from 30~ acrylamide and 0.8% bis-(acrylamide) and contained 0.375 M Tris, pH 8.8, 0.1% SDS, 0.05~ TEMED, and 0.46% ammonium persulfate). The gel is dried and autoradiography performed with Agfa Curix ~P2 X-ray film. The relevant radioactive bands are cut and counted in the Cerenkov mode. The fast phase of autophosphorylation continues for another lO minutes. The extent of phosphorylation completed in the first lO-s at l5~C
comprises l/3 of the total autophosphorylation signal and probably reflects the phosphorylation of the first site on the receptor. The lO-s interval is therefore chosen for use in subsequent autophosphorylation experiments.
ATP and EGF Dependence of Auto~hosphorylation WGA-purified EGF receptor from A431 cells tO.5 ~g/assay is activated with EGF (0.85 ~M~ for 20 minutes at 4C. The assay is performed at 15C and initiated by addition of Mg(Ac) 2 (60 mmol), Tris-Mes buffer, pH 7.6 (50 mmol), [32P]ATP (carrier free, 5 ~Ci~assay), and increasing concentrations of nonradioactive ATP. The assay is terminated after lO-s by addition of SDS sample buffer. The samples are run on a 6%
SDS polyacrylamide gel. The gel is dried and autoradiographed as described above. The relevant radioactive bands are cut and counted in the Cerenkov mode. the Km for ATP determined in this fashion is found to be 7.2 ~M. With use of the lO-s assay protocol, the EGF concentration dependence of EGFRK
autophosphorylation is determined.
Inhibition of Copoly(Glu4Tyr) Phosphorylation by Insulin-ReceDtor Kinase (InsRK) Rat liver membranes are prepared from the livers of 6-week-old rats as described by Cuatrecasas. WGA-purified insulin receptor is prepared according to Zick et al. WGA-purified rat liver InsRK (1.25 ~g) is preincubated with or without 330 nM insulin in 50 mmol Tris-Mes buffer, pH 7.6, for W091/16305 2 0 $ ~ ~ ~ 2 PCT/USgl/02597 30 minutes at 22C. The assay is performed at 22C and initiated by addition of a mixture which contains Mg(Ac)2 ~60 mmol), NaV03 (40 ~M), [~-32P~ATP (125 ~M, 3-5 ~Ci/assay), and poly(GT) [poly(Glu4Tyr)] at three concentrations: whenever an inhibitor is tested, it is added at the proper concentration.
The final concentration of insulin in the assay is 125 nM.
The total volume of the assay is 40 ~l. After 20 minutes, aliquots of 30 ~l are applied on Whatman 3-mm paper and soaked in cold 10% TCA, containing O.Ol M sodium pyrophosphate.
After being washed overnight, the papers are dried and counted, measuring Cerenkov radiation. The InsRk-catalyzed phosphorylation of poly(GT) obeys Michaelis-Menten kinetics.
Inhibition of EGFR Autophos~horylation A43l cells were grown to confluence on human fibronectin coated tissue culture dishes. After washing 2 times with ice-cold PBS, cells were lysed by the addition of 500 ~l/dish of lysis buffer (50 mmol Hepes, p~ 7.5, 150 mmol NaCl, 1.5 mmol Mg Cl2, l mmol EGTA, lO~ glycerol, 1% triton X-lO0, l mmol PMSF, l mg/ml aprotinin, l mg/ml leupeptin) and incubating 5 minutes at 4C. After EGF stimulation (500 ~g/ml lO minutes at 37C) immunoprecipitation was performed with anti EGF-R (Ab 108) and the autophosphorylation reaction (50 ~l aliquots, 3 ~Ci t~-32P]ATP) sample was carried out in the presence of 2 or lO ~M of compound, for 2 minutes at 4 C. The reaction was stopped by adding hot electrophoresis sample buffer. SDS-PAGE
analysis (7.5% els) was followed by autoradiography and the reaction was quantitated by densitometry scanning of the x-ray films. In order to test the compounds for selective inhibition, the procedure is repeated using PDGF stimulation in place of EGF stimulation. rhe results of this test are summarized in Table II below.
Table II
IC50 (~M) Example EGF PDGF
8 l 20 WO91/1630S 2 ~ 8 ~ ~ ~ 2 PCT/US91/0259-~
The results of this assay show that the compounds of the present inv~ntion inhibit EGF receptor kinase better than they inhibit PDGF receptor Xinase.
Inhibition of Cell Proliferation as Measured by Inhibition of DNA Synthesls~
Cells were seeded at 1 x 105 cells per well in 24-well Costar dishes pre-coated with human fibronectin (by incubating for 30 minutes at room temperature with 10 ~g/0.5 ml/well).
The cells were grown to confluence for 2 days. The medium was changed to DMEM containing 0.5 calf serum for 36-48 hours and the cells were then incubated with EGF (Toyobo, New York, NY) (20 ng/ml) or serum (10% calf serum; and di~Leren~
concentrations of the inhibitory compounds. [3H]thymidine, (NEN, Boston, MA) was added 16-24 hours later at 0.5~Ci/ml for 2 hours. TCA precipitable material was quantitated by scintillation counting fC~.
Cell Culture Cells termed HER 14 and K721A (=DK) were prepared by trans~ecting NlH3T3 cells (clone 2.2) (From C. Fryling, NCI, NIH), which lack endogenous EGF-receptors, with cDNA
constructs of wild-type EGF-receptor or mutant EGF-receptor lacking tyrosine kinase activity (in which Lys 721 at the ATP-binding site was replaced by an Ala residue, respectively).
All cells were grown in ~EM with 10% calf serum (Hyclone, Loganl Utah).
The results obtained by the above experimental methods evidence the useful protein tyrosine kinase inhibition properties of the compounds within the scope of the present invention.
Time_Dependence_oE EGF-Receptor Auto~hos~horYlation WGA-purified EGF receptor from A431 cells (0.5 ~g/assay) is activated with EGF (800 nM) for 20 minutes at 4C. The reaction is initiated by the addition of Mg(Ac)2 (60 mmol), Tris-~es buffer, pH 7.6 (50 mmol), and [32P]ATP (20 ~M, 5 ~Ci/assay). The reaction is conducted at either 4 or l5C and 2~3~2 WO91/16305 PCr/US91/02' terminated by addition of sodium dodecyl sulfate (SDS) sample buffer (10% glycerol, 50 mmol Tris, pH 6.8, 5~ ~-mercapto-ethanol, and 3% (SDS). The samples are run on a 8~ SDS
polyacrylamide gel (SDS-PAGE) (prepared from 30~ acrylamide and 0.8% bis-(acrylamide) and contained 0.375 M Tris, pH 8.8, 0.1% SDS, 0.05~ TEMED, and 0.46% ammonium persulfate). The gel is dried and autoradiography performed with Agfa Curix ~P2 X-ray film. The relevant radioactive bands are cut and counted in the Cerenkov mode. The fast phase of autophosphorylation continues for another lO minutes. The extent of phosphorylation completed in the first lO-s at l5~C
comprises l/3 of the total autophosphorylation signal and probably reflects the phosphorylation of the first site on the receptor. The lO-s interval is therefore chosen for use in subsequent autophosphorylation experiments.
ATP and EGF Dependence of Auto~hosphorylation WGA-purified EGF receptor from A431 cells tO.5 ~g/assay is activated with EGF (0.85 ~M~ for 20 minutes at 4C. The assay is performed at 15C and initiated by addition of Mg(Ac) 2 (60 mmol), Tris-Mes buffer, pH 7.6 (50 mmol), [32P]ATP (carrier free, 5 ~Ci~assay), and increasing concentrations of nonradioactive ATP. The assay is terminated after lO-s by addition of SDS sample buffer. The samples are run on a 6%
SDS polyacrylamide gel. The gel is dried and autoradiographed as described above. The relevant radioactive bands are cut and counted in the Cerenkov mode. the Km for ATP determined in this fashion is found to be 7.2 ~M. With use of the lO-s assay protocol, the EGF concentration dependence of EGFRK
autophosphorylation is determined.
Inhibition of Copoly(Glu4Tyr) Phosphorylation by Insulin-ReceDtor Kinase (InsRK) Rat liver membranes are prepared from the livers of 6-week-old rats as described by Cuatrecasas. WGA-purified insulin receptor is prepared according to Zick et al. WGA-purified rat liver InsRK (1.25 ~g) is preincubated with or without 330 nM insulin in 50 mmol Tris-Mes buffer, pH 7.6, for W091/16305 2 0 $ ~ ~ ~ 2 PCT/USgl/02597 30 minutes at 22C. The assay is performed at 22C and initiated by addition of a mixture which contains Mg(Ac)2 ~60 mmol), NaV03 (40 ~M), [~-32P~ATP (125 ~M, 3-5 ~Ci/assay), and poly(GT) [poly(Glu4Tyr)] at three concentrations: whenever an inhibitor is tested, it is added at the proper concentration.
The final concentration of insulin in the assay is 125 nM.
The total volume of the assay is 40 ~l. After 20 minutes, aliquots of 30 ~l are applied on Whatman 3-mm paper and soaked in cold 10% TCA, containing O.Ol M sodium pyrophosphate.
After being washed overnight, the papers are dried and counted, measuring Cerenkov radiation. The InsRk-catalyzed phosphorylation of poly(GT) obeys Michaelis-Menten kinetics.
Inhibition of EGFR Autophos~horylation A43l cells were grown to confluence on human fibronectin coated tissue culture dishes. After washing 2 times with ice-cold PBS, cells were lysed by the addition of 500 ~l/dish of lysis buffer (50 mmol Hepes, p~ 7.5, 150 mmol NaCl, 1.5 mmol Mg Cl2, l mmol EGTA, lO~ glycerol, 1% triton X-lO0, l mmol PMSF, l mg/ml aprotinin, l mg/ml leupeptin) and incubating 5 minutes at 4C. After EGF stimulation (500 ~g/ml lO minutes at 37C) immunoprecipitation was performed with anti EGF-R (Ab 108) and the autophosphorylation reaction (50 ~l aliquots, 3 ~Ci t~-32P]ATP) sample was carried out in the presence of 2 or lO ~M of compound, for 2 minutes at 4 C. The reaction was stopped by adding hot electrophoresis sample buffer. SDS-PAGE
analysis (7.5% els) was followed by autoradiography and the reaction was quantitated by densitometry scanning of the x-ray films. In order to test the compounds for selective inhibition, the procedure is repeated using PDGF stimulation in place of EGF stimulation. rhe results of this test are summarized in Table II below.
Table II
IC50 (~M) Example EGF PDGF
8 l 20 WO91/1630S 2 ~ 8 ~ ~ ~ 2 PCT/US91/0259-~
The results of this assay show that the compounds of the present inv~ntion inhibit EGF receptor kinase better than they inhibit PDGF receptor Xinase.
Inhibition of Cell Proliferation as Measured by Inhibition of DNA Synthesls~
Cells were seeded at 1 x 105 cells per well in 24-well Costar dishes pre-coated with human fibronectin (by incubating for 30 minutes at room temperature with 10 ~g/0.5 ml/well).
The cells were grown to confluence for 2 days. The medium was changed to DMEM containing 0.5 calf serum for 36-48 hours and the cells were then incubated with EGF (Toyobo, New York, NY) (20 ng/ml) or serum (10% calf serum; and di~Leren~
concentrations of the inhibitory compounds. [3H]thymidine, (NEN, Boston, MA) was added 16-24 hours later at 0.5~Ci/ml for 2 hours. TCA precipitable material was quantitated by scintillation counting fC~.
Cell Culture Cells termed HER 14 and K721A (=DK) were prepared by trans~ecting NlH3T3 cells (clone 2.2) (From C. Fryling, NCI, NIH), which lack endogenous EGF-receptors, with cDNA
constructs of wild-type EGF-receptor or mutant EGF-receptor lacking tyrosine kinase activity (in which Lys 721 at the ATP-binding site was replaced by an Ala residue, respectively).
All cells were grown in ~EM with 10% calf serum (Hyclone, Loganl Utah).
The results obtained by the above experimental methods evidence the useful protein tyrosine kinase inhibition properties of the compounds within the scope of the present invention.
Claims (5)
1. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a heteroarylethenediyl or a heteroarylethenediyl aryl compound, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl group can be mono- or bicyclic heteroaryl and the aryl group can be or mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents.
2. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a heteroarylethenediyl or a heteroarylethenediyl aryl compound, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl group can be mono- or bicyclic heteroaryl and the aryl group can be or mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents.
3. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 2.
4. A compound of the formula wherein:
W is a heteroaryl ring system having an about 5 to about 7-membered monocyclic ring including 1 or 2 N, O or S
atoms, or an about 8- to about 12-membered bicyclic ring including 1 to about 4 N, O or S atoms, said ring system optionally substituted with one to about three R4 groups;
R1 is alkyl, -CN, -CONRR, -CSNRR or -COOR;
R is hydrogen, alkyl or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR, -CH=C(CN) 2, -C(NH2)=C(CN)2, , , or an about 9- to about 11-membered bicyclic aryl carbocyclic riny system or an about 12- to about 15-membered tricyclic aryl carbocyclic ring system, said ring system optionally substituted with one to about three R4 groups;
R3 is hydrogen, alkyl, -CN, -CH2CN, -CONRR, -CSNRR, -COOR or -CH=C(CN)CONH2;
each R4 is independently alkyl, hydroxy, alkoxy, halo, amino, mono- and di-alkylamino, acetylamino, alkylthio, -CN, -CF3, nitro, -COOR, -CONRR, -CSNRR, -CHO, -CH=CHCOOH, -NHCO(CH2)2COOH or morpholino;
R5 is amino, -CONH2, or ;
each R6 is independently hydrogen, alkyl, hydroxy, alkoxy or halo;
each R7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0 to about 6; and m is 1 to about 7;
with the proviso that when both R1 and R2 are -CN, W is not furyl or thienyl.
5. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 4, or a pharmaceutically acceptable salt thereof.
WO 91/16305 PCT/US91/025?
6. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 5.
7. A compound according to Claim 4 wherein:
W is a 5- or 6-membered monocyclic aryl ring including 1 or 2 N, O or S atoms, or a 9- or 10-membered bicyclic aryl ring including 1 to 4 N, O or S atoms, said ring optionally substituted with one to about three R4 groups;
R1 is -CN, -CONRR, -CSNRR or -COOR;
R is hydrogen, alkyl or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR or ;
R3 is hydrogen;
each R4 is independently alkyl, hydroxy, alkoxy or halo;
R5 is amino, -CONH2, or ;
each R6 is independently hydrogen or alkyl;
each R7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0-4; and m is 2-6.
8. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 7, or a pharmaceutically acceptable salt thereof.
9. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 8.
10. A compound according to Claim 7 wherein W is furyl, pyrrolyl, thienyl, thiazolyl, pyridyl, imidazolyl, isoimidazolyl, pyridazinyl, pyrimdinyl, benzofuranyl, indolyl, indolinyl, indolinonyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromenyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl.
11. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 10, or a pharmaceutically acceptable salt thereof.
WO 91/16305 PCT/US91/025?
12. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 11.
13. A compound according to Claim 10 wherein:
W is pyridyl, indolyl, imidazolyl, benzothiazolyl, 1,3- benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl; and R5 is or .
14. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 13, or a pharmaceutically acceptable salt thereof.
15. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 14.
16. A compound according to Claim 13 wherein:
each R4 is independently hydroxy, lower alkyl, lower alkoxy or halo; and each R7 is independently lower alkyl, halo, alkoxy, hydroxy, nitro, carboxy or carbalkoxy.
17. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 16, or a pharmaceutically acceptable salt thereof.
18. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 17.
19. A compound according to Claim 16 wherein said compound is 2-(4-pyridyl)-3-(9-phenanthryl)-2-propenenitrile.
20. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 19, or a pharmaceutically acceptable salt thereof.
21. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 20.
WO 91/16305 PCT/US91/025?
22. A compound according to Claim 16 wherein said compound is 2-(3,4-dihydroxybenzoyl)-3-(5-indolyl)-2-propenenitrile.
23. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
24. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 23.
25. A compound according to Claim 16 wherein said compound is 2-(3,4-dihydroxybenzoyl)-3-(3-indolyl)-2-propenenitrile.
26. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 25, or a pharmaceutically acceptable salt thereof.
27. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 26.
28. A method for the treatment of psoriasis in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 2.
29. A method for the treatment of psoriasis is a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 5.
30. A method for the treatment of atherosclerosis in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 2.
31. A method for the treatment of atherosclerosis in a patient suffering from such disorder comprising the administration to the patient of a composition according to
W is a heteroaryl ring system having an about 5 to about 7-membered monocyclic ring including 1 or 2 N, O or S
atoms, or an about 8- to about 12-membered bicyclic ring including 1 to about 4 N, O or S atoms, said ring system optionally substituted with one to about three R4 groups;
R1 is alkyl, -CN, -CONRR, -CSNRR or -COOR;
R is hydrogen, alkyl or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR, -CH=C(CN) 2, -C(NH2)=C(CN)2, , , or an about 9- to about 11-membered bicyclic aryl carbocyclic riny system or an about 12- to about 15-membered tricyclic aryl carbocyclic ring system, said ring system optionally substituted with one to about three R4 groups;
R3 is hydrogen, alkyl, -CN, -CH2CN, -CONRR, -CSNRR, -COOR or -CH=C(CN)CONH2;
each R4 is independently alkyl, hydroxy, alkoxy, halo, amino, mono- and di-alkylamino, acetylamino, alkylthio, -CN, -CF3, nitro, -COOR, -CONRR, -CSNRR, -CHO, -CH=CHCOOH, -NHCO(CH2)2COOH or morpholino;
R5 is amino, -CONH2, or ;
each R6 is independently hydrogen, alkyl, hydroxy, alkoxy or halo;
each R7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0 to about 6; and m is 1 to about 7;
with the proviso that when both R1 and R2 are -CN, W is not furyl or thienyl.
5. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 4, or a pharmaceutically acceptable salt thereof.
WO 91/16305 PCT/US91/025?
6. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 5.
7. A compound according to Claim 4 wherein:
W is a 5- or 6-membered monocyclic aryl ring including 1 or 2 N, O or S atoms, or a 9- or 10-membered bicyclic aryl ring including 1 to 4 N, O or S atoms, said ring optionally substituted with one to about three R4 groups;
R1 is -CN, -CONRR, -CSNRR or -COOR;
R is hydrogen, alkyl or aralkyl;
R2 is -W, -CN, -CONHR5, -CONRR, -COOR, -CSNRR or ;
R3 is hydrogen;
each R4 is independently alkyl, hydroxy, alkoxy or halo;
R5 is amino, -CONH2, or ;
each R6 is independently hydrogen or alkyl;
each R7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
n is 0-4; and m is 2-6.
8. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 7, or a pharmaceutically acceptable salt thereof.
9. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 8.
10. A compound according to Claim 7 wherein W is furyl, pyrrolyl, thienyl, thiazolyl, pyridyl, imidazolyl, isoimidazolyl, pyridazinyl, pyrimdinyl, benzofuranyl, indolyl, indolinyl, indolinonyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromenyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl.
11. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 10, or a pharmaceutically acceptable salt thereof.
WO 91/16305 PCT/US91/025?
12. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 11.
13. A compound according to Claim 10 wherein:
W is pyridyl, indolyl, imidazolyl, benzothiazolyl, 1,3- benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl; and R5 is or .
14. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 13, or a pharmaceutically acceptable salt thereof.
15. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 14.
16. A compound according to Claim 13 wherein:
each R4 is independently hydroxy, lower alkyl, lower alkoxy or halo; and each R7 is independently lower alkyl, halo, alkoxy, hydroxy, nitro, carboxy or carbalkoxy.
17. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 16, or a pharmaceutically acceptable salt thereof.
18. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 17.
19. A compound according to Claim 16 wherein said compound is 2-(4-pyridyl)-3-(9-phenanthryl)-2-propenenitrile.
20. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 19, or a pharmaceutically acceptable salt thereof.
21. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 20.
WO 91/16305 PCT/US91/025?
22. A compound according to Claim 16 wherein said compound is 2-(3,4-dihydroxybenzoyl)-3-(5-indolyl)-2-propenenitrile.
23. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
24. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 23.
25. A compound according to Claim 16 wherein said compound is 2-(3,4-dihydroxybenzoyl)-3-(3-indolyl)-2-propenenitrile.
26. A pharmaceutical composition for inhibiting cell proliferation in a patient suffering from such disorder comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of a compound according to Claim 25, or a pharmaceutically acceptable salt thereof.
27. A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 26.
28. A method for the treatment of psoriasis in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 2.
29. A method for the treatment of psoriasis is a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 5.
30. A method for the treatment of atherosclerosis in a patient suffering from such disorder comprising the administration to the patient of a composition according to Claim 2.
31. A method for the treatment of atherosclerosis in a patient suffering from such disorder comprising the administration to the patient of a composition according to
Claim 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50998190A | 1990-04-16 | 1990-04-16 | |
US509,981 | 1990-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2080582A1 true CA2080582A1 (en) | 1991-10-17 |
Family
ID=24028875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002080582A Abandoned CA2080582A1 (en) | 1990-04-16 | 1991-04-16 | Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0527181A4 (en) |
JP (1) | JPH05507072A (en) |
AU (1) | AU662480B2 (en) |
CA (1) | CA2080582A1 (en) |
IL (1) | IL97873A0 (en) |
WO (1) | WO1991016305A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0584222B1 (en) * | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
EP0680950B1 (en) * | 1993-11-17 | 2001-05-23 | Kyowa Hakko Kogyo Co., Ltd. | Propenone derivatives |
GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
EP0770601A4 (en) * | 1995-05-10 | 1998-08-05 | Kyowa Hakko Kogyo Kk | PROPENONE DERIVATIVES |
US6444694B1 (en) * | 1995-06-06 | 2002-09-03 | Wyeth | Styryl benzimidazole derivatives |
US5710164A (en) * | 1995-06-06 | 1998-01-20 | American Home Products Corporation | Diheterocyclic styryl nitriles |
CA2224874A1 (en) * | 1995-06-19 | 1997-03-13 | Ontogen Corporation | Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors |
ATE259353T1 (en) * | 1995-12-01 | 2004-02-15 | Kyowa Hakko Kogyo Kk | PROPENONE DERIVATIVES |
PL1701941T3 (en) | 2003-12-11 | 2012-11-30 | Univ Texas | Compounds for treatment of cell proliferative diseases |
CA2648003C (en) | 2006-03-31 | 2014-07-08 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
ES2521676T3 (en) | 2008-07-08 | 2014-11-13 | Board Of Regents, The University Of Texas System | New proliferation inhibitor and activation agents for signal transducers and transcription activators (STATS) |
JP2019510088A (en) * | 2016-03-17 | 2019-04-11 | ザ ジョンズ ホプキンス ユニバーシティーThe Johns Hopkins University | Method for preventing or treating Parkinson's disease by farnesylation of PARIS |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605382A (en) * | 1975-06-04 | 1976-12-07 | Sumitomo Chemical Co | PROCESS FOR PREPARING INDOLE DERIVATIVES. |
AU632992B2 (en) * | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2080581A1 (en) * | 1990-04-16 | 1991-10-17 | Alfred P. Spada | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
-
1991
- 1991-04-16 CA CA002080582A patent/CA2080582A1/en not_active Abandoned
- 1991-04-16 EP EP19910908779 patent/EP0527181A4/en not_active Withdrawn
- 1991-04-16 WO PCT/US1991/002597 patent/WO1991016305A1/en not_active Application Discontinuation
- 1991-04-16 IL IL97873A patent/IL97873A0/en unknown
- 1991-04-16 AU AU77568/91A patent/AU662480B2/en not_active Ceased
- 1991-04-16 JP JP91508377A patent/JPH05507072A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1991016305A1 (en) | 1991-10-31 |
JPH05507072A (en) | 1993-10-14 |
EP0527181A1 (en) | 1993-02-17 |
EP0527181A4 (en) | 1993-04-07 |
AU7756891A (en) | 1991-11-11 |
AU662480B2 (en) | 1995-09-07 |
IL97873A0 (en) | 1992-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5196446A (en) | Certain indole compounds which inhibit EGF receptor tyrosine kinase | |
AU658567B2 (en) | Styryl-substituted indole and pyridyl compounds | |
EP0580598B1 (en) | Styryl-substituted heteroaryl compounds which inhibit egf receptor tyrosine kinase | |
US5656655A (en) | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase | |
US5217999A (en) | Styryl compounds which inhibit EGF receptor protein tyrosine kinase | |
EP0584222B1 (en) | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase | |
US5710158A (en) | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | |
US5714493A (en) | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | |
USRE37650E1 (en) | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | |
USRE36256E (en) | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | |
AU646006B2 (en) | Diaza compounds | |
WO1991016892A1 (en) | Styryl compounds which inhibit egf receptor protein tyrosine kinase | |
JPH11507355A (en) | Aryl and heteroaryl quinazoline compounds that selectively inhibit the autophosphorylation ability of protein tyrosine kinase HER-2 | |
AU662480B2 (en) | Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase | |
US5418245A (en) | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinase | |
FI100530B (en) | Process for the preparation of substituted diaminophthalimides and their analogues | |
US5476851A (en) | Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase | |
MXPA97001820A (en) | Compounds of pirazolo [3,4-g] quinoxaline queinhiben protein tyrosine kinase receptor dep | |
US4652565A (en) | Piperazine derivatives, their production and pharmaceutical compositions containing them | |
US4447607A (en) | Dibenzo diazacines | |
IL99762A (en) | Alpha-cyano-styryl-substituted pyridyl compounds which inhibit egf receptor tyrosine kinase and pharmaceutical compositions containing them | |
IE853326L (en) | Allylic amines | |
CZ310092B6 (en) | A heterocyclic compound for the inhibition of growth of malignant tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |